AI assistant
VALIRX PLC — Remuneration Information 2014
Oct 23, 2014
7998_dirs_2014-10-23_0ef752b7-327c-4913-9b15-c681078c8394.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 1088V
ValiRx PLC
23 October 2014
23 October 2014
ValiRx Plc
("ValiRx" or the "Company")
Grant of options
ValiRx Plc (AIM: VAL), the AIM-quoted life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that on 22 October 2014, it granted 149,000,000 options over ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") to certain employees and directors of the Company, as set out in the table below.
| Name of director | Number of shares held | % of issued share capital | Number of existing options | Number of new options granted | Total options now held | Options held as % of issued share capital |
| Satu Vainikka | 23,113,714 | 0.79% | 35,000,000 | 24,000,000 | 59,000,000 | 2.02% |
| George Morris | 18,535,993 | 0.63% | 28,750,000 | 22,000,000 | 50,750,000 | 1.74% |
| Gerry Desler | 12,733,921 | 0.44% | 28,400,000 | 22,000,000 | 50,400,000 | 1.73% |
| Kevin Alexander | 8,034,843 | 0.28% | 26,400,000 | 20,000,000 | 46,400,000 | 1.59% |
| Oliver de Giorgio-Miller | 2,444,411 | 0.08% | 23,000,000 | 20,000,000 | 43,000,000 | 1.47% |
| Seppo Makinen | 1,273,387 | 0.04% | 8,000,000 | 20,000,000 | 28,000,000 | 0.96% |
| Total Directors | 66,136,269 | 2.26% | 149,550,000 | 128,000,000 | 277,550,000 | 9.51% |
| Other employees | Nil | Nil | 23,100,000 | 21,000,000 | 44,100,000 | 1.51% |
| Total | 66,136,269 | 2.26% | 172,650,000 | 149,000,000 | 321,650,000 | 11.02% |
The new options were granted under the Company's stock option plan and have an exercise price of 0.36p pence. The new options are exercisable from 22 October 2014 until 21 October 2024.
Following the grant of the new options, the total number of Ordinary Shares under option held by directors, which could be issued, is 277,550,000 Ordinary Shares, representing approximately 9.51 per cent. of the current issued share capital of the Company.
In addition, a further 21,000,000 options have been granted to employees of the Company at an exercise price of 0.36 pence which are exercisable until 21 October 2024.
The issued share capital of the Company comprises 2,921,043,420 ordinary shares of 0.1 pence each.
For more information, please contact:
| ValiRx plc | Tel: +44 (0)20 3008 4416 |
| Dr Satu Vainikka | www.ValiRx.com |
| Cairn Financial Advisers LLP (Nominated Adviser) | Tel: +44 (0)20 7148 7900 |
| Liam Murray / Avi Robinson | |
| Daniel Stewart & Company Plc (Broker) | Tel: +44 (0)20 7776 6550 |
| Martin Lampshire/ Mark Treharne | |
| Peckwater PR | Tel: +44 (0)7879 458 364 |
| Tarquin Edwards | [email protected] |
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSGCBDGGSDBGSX